Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure

被引:11
作者
Liu, Wenxia [1 ]
Sun, Zhuang [2 ]
An, Yunfei [1 ]
Liu, Yating [1 ]
Fan, Haiyan [1 ]
Han, Jun [1 ]
Sun, Bin [1 ]
机构
[1] Liaocheng Univ, Inst BioPharmaceut Res, 1 Hunan Rd, Liaocheng 252000, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, 1295 Dingxi Rd, Shanghai 200050, Peoples R China
基金
中国国家自然科学基金;
关键词
Amide naphthyl compounds; Scaffold growth; Antifungal activity; Dual target inhibition; DRUG-RESISTANCE; MECHANISMS; DISCOVERY; EPIDEMIOLOGY; DESIGN; SE;
D O I
10.1016/j.ejmech.2021.113972
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
With the increase of fungal infection and drug resistance, it is becoming an urgent task to discover the highly effective antifungal drugs. In the study, we selected the key ergosterol bio-synthetic enzymes (Squalene epoxidase, SE; 14 alpha-demethylase, CYP51) as dual-target receptors to guide the construction of novel antifungal compounds, which could achieve the purpose of improving drug efficacy and reducing drug-resistance. Three different series of amide naphthyl compounds were generated through the method of skeleton growth, and their corresponding target products were synthesized. Most of com-pounds displayed the obvious biological activity against different Candida spp. and Aspergillus fumigatus. Among of them, target compounds 14a-2 and 20b-2 not only possessed the excellent broad-spectrum anti-fungal activity (MIC50, 0.125-2 mu g/mL), but also maintained the anti-drug-resistant fungal activity (MIC50, 1-4 mu g/mL). Preliminary mechanism study revealed the compounds (14a-2, 20b-2) could block the bio-synthetic pathway of ergosterol by inhibiting the dual-target (SE/CYP51) activity, and this finally caused the cleavage and death of fungal cells. In addition, we also discovered that compounds 14a-2 and 20b-2 with low toxic and side effects could exert the excellent therapeutic effect in mice model of fungal infection, which was worthy for further in-depth study. (c) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:24
相关论文
共 36 条
  • [1] Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation
    An, Yunfei
    Dong, Yue
    Liu, Min
    Han, Jun
    Zhao, Liyu
    Sun, Bin
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 210
  • [2] Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
    Arendrup, Maiken Cavling
    Patterson, Thomas F.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S445 - S451
  • [3] Candidiasisand Mechanisms of Antifungal Resistance
    Bhattacharya, Somanon
    Sae-Tia, Sutthichai
    Fries, Bettina C.
    [J]. ANTIBIOTICS-BASEL, 2020, 9 (06): : 1 - 19
  • [4] Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications
    Bian, Yuemin
    Xie, Xiang-Qun
    [J]. AAPS JOURNAL, 2018, 20 (03):
  • [5] Epigenetic mechanisms of drug resistance in fungi
    Chang, Zanetta
    Yadav, Vikas
    Lee, Soo Chan
    Heitman, Joseph
    [J]. FUNGAL GENETICS AND BIOLOGY, 2019, 132
  • [6] Choosing the Right Antifungal Agent in ICU Patients
    Chatelon, Jeanne
    Cortegiani, Andrea
    Hammad, Emmanuelle
    Cassir, Nadim
    Leone, Marc
    [J]. ADVANCES IN THERAPY, 2019, 36 (12) : 3308 - 3320
  • [7] Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors
    Dong, Yue
    Liu, Min
    Wang, Jian
    Ding, Zhuang
    Sun, Bin
    [J]. RSC ADVANCES, 2019, 9 (45) : 26302 - 26314
  • [8] A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*
    Elewski, B.
    Brand, S.
    Degenhardt, T.
    Curelop, S.
    Pollak, R.
    Schotzinger, R.
    Tavakkol, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (02) : 270 - 280
  • [9] Enoch DA, 2017, METHODS MOL BIOL, V1508, P17, DOI 10.1007/978-1-4939-6515-1_2
  • [10] Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures
    Erlanson, Daniel A.
    Davis, Ben J.
    Jahnke, Wolfgang
    [J]. CELL CHEMICAL BIOLOGY, 2019, 26 (01): : 9 - 15